Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
8.11
-0.83 (-9.28%)
At close: Aug 30, 2024, 4:00 PM
8.12
+0.01 (0.12%)
After-hours: Aug 30, 2024, 5:01 PM EDT
Windtree Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
4.80M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tonix Pharmaceuticals Holding | 12.46M |
iCoreConnect | 10.27M |
MSP Recovery | 7.51M |
Elevai Labs | 2.47M |
Silo Pharma | 72.10K |
Ainos | 65.12K |
Titan Pharmaceuticals | 3.00K |
WINT News
- 11 days ago - Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 17 days ago - Windtree Announces New Additions and Changes to Its Board of Directors - GlobeNewsWire
- 5 weeks ago - Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - GlobeNewsWire
- 4 months ago - Windtree Therapeutics Regains Compliance with Nasdaq - GlobeNewsWire
- 4 months ago - What made Windtree Therapeutics stock tank 20% on Monday? - Invezz
- 4 months ago - Windtree Therapeutics Announces Reverse Stock Split - GlobeNewsWire
- 4 months ago - Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 5 months ago - Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing - GlobeNewsWire